American Society of HematologyMarrow or Peripheral Blood for Allogeneic Transplant: Are We Ignoring the Data?

Despite peripheral blood making up 80% of all of hematopoietic cell transplants, there are similar rates of overall survival, disease-free survival, and transplant-related mortality when comparing marrow and peripheral blood as graft sources. Chronic graft-versus-host disease (GVHD) and cytokine release syndrome (CRS) are more significant in those who received peripheral blood, yet the standard of […]

American Society of HematologyPosttransplantation MRD Monitoring in Patients w. AML by Next-Generation Sequencing Using DTA and Non-DTA Mutations

In this article from Blood Advances highlighted by helpful visual abstracts, two key points are discussed. First, patient-specific next-generation sequencing (NGS)-based measurable residual disease (MRD) monitoring using non-DTA mutations after allogeneic hematopoietic cell transplantation (alloHCT) is independently prognostic for relapse and survival. Second, the kinetics rather than a single time point should be further evaluated […]

American Society of Clinical OncologyNational Marrow Donor Program–Sponsored Multicenter, Phase II Trial of HLA-Mismatched Unrelated Donor Bone Marrow Transplantation Using Post-Transplant Cyclophosphamide

In this Original Report from the Journal of Clinical Oncology, the authors hypothesized that hematopoietic cell transplantation (HCT) with a mismatched unrelated donor (MMUD) using post-transplant cyclophosphamide (PTCy), a novel strategy successful in overcoming genetic disparity using mismatched related donors, would be feasible and increase access to HCT. Was their hypothesis correct?

Millennium Medical PublishingHighlights in Graft-vs-Host Disease From the 2021 Transplantation & Cellular Therapy (TCT) Meetings of the ASTCT and the CIBMTR

From the pages of Clinical Advances in Hematology & Oncology comes this review of selected presentations from the 2021 TCT Meetings Digital Experience, which took place February 8-12, 2021. Expert commentary is provided by Dr. Yi-Bin Chen, Director of the Hematopoietic Cell Transplant & Cellular Therapy Program at Massachusetts General Hospital.